Arqule, Inc.
Arqule, Inc.
http://www.arqule.com/ Promotes their activated checkpoint therapy platform. Headquartered in Woburn, Massachusetts. (Nasdaq: ARQL) Cancer > Research and Development Investor & Media Relations We are pursuing a number of exciting and innovative approaches to cancer therapy at ArQule. These are the result of unique biology and world-class chemistry capabilities that differentiate us from other development-stage oncology companies. We are also moving rapidlyFor detailed information visit the website, please... ArQule ARQ 197 ARQ197 c-Met c-MET cMeT c-Met inhibitor Selective c-MET inhibitor Selective inhibitor of the c-Met receptor tyrosine kinase
Write a Review
Add to My Favorite
Refer it to Friend
Report Broken Link
Google Ads
Other links at Cancer > Research and Development
Develops drugs for asthma, cancer, cystic fibrosis and age-related macular degeneration. Includes overview of clinical trials, investor information and news from company in Plymouth Meeting, Pennsylvania. (Nasdaq: GENR)
Category:
Licenses tumor-activated prodrug technology, for development of small molecule anticancer agents, to optimise potency and toxicity. Manufacturing in Norwood, and headquarters in Cambridge, Massachusetts. (Nasdaq: IMGN)
Category:
Intending to discovery, develop and commercialize novel therapies for cancer and blood cell disorders. Profile includes technology overview, investor data, and careers in Dublin, California. (Nasdaq: SUPG)
Category:
Main Category
14
100
31
5
50
7
11
40
166
20
59
76
24
75
110
142
7
8
13
30
66
Join Mailing List
Joining mailing list will entitle you
to receive occasional emails informing you of news and
updates to the site and any special offers that may be
of interest to you.
Top 10
Directory Statistics
Links: 1054
Categories: 36
Pagerank Statistics
Yahoo News